American International Group Inc. increased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 7.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 22,681 shares of the biopharmaceutical company’s stock after buying an additional 1,500 shares during the period. American International Group Inc.’s holdings in TG Therapeutics were worth $264,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently modified their holdings of TGTX. Jennison Associates LLC bought a new position in shares of TG Therapeutics during the first quarter valued at about $16,034,000. Columbus Circle Investors increased its position in shares of TG Therapeutics by 29.3% in the first quarter. Columbus Circle Investors now owns 1,004,421 shares of the biopharmaceutical company’s stock valued at $11,702,000 after buying an additional 227,722 shares in the last quarter. State Street Corp increased its position in shares of TG Therapeutics by 6.7% in the fourth quarter. State Street Corp now owns 679,115 shares of the biopharmaceutical company’s stock valued at $3,157,000 after buying an additional 42,760 shares in the last quarter. EAM Investors LLC bought a new position in shares of TG Therapeutics during the first quarter valued at about $3,856,000. Finally, Candriam Luxembourg S.C.A. increased its position in shares of TG Therapeutics by 40.0% in the first quarter. Candriam Luxembourg S.C.A. now owns 315,000 shares of the biopharmaceutical company’s stock valued at $3,670,000 after buying an additional 90,000 shares in the last quarter. Hedge funds and other institutional investors own 46.05% of the company’s stock.
Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) opened at 10.35 on Friday. The stock’s market capitalization is $638.14 million. The stock’s 50 day moving average is $11.10 and its 200 day moving average is $9.77. TG Therapeutics, Inc. has a 52 week low of $4.10 and a 52 week high of $15.35.
TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by $0.10. The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative net margin of 60,613.16% and a negative return on equity of 135.31%. Analysts anticipate that TG Therapeutics, Inc. will post ($1.81) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “American International Group Inc. Has $264,000 Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://stocknewstimes.com/2017/08/05/tg-therapeutics-inc-nasdaqtgtx-stake-increased-by-american-international-group-inc-updated.html.
Several research analysts recently issued reports on TGTX shares. BidaskClub downgraded TG Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 6th. Zacks Investment Research raised shares of TG Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Thursday, July 13th. Raymond James Financial, Inc. reaffirmed a “buy” rating on shares of TG Therapeutics in a research note on Friday, April 21st. FBR & Co reaffirmed a “buy” rating on shares of TG Therapeutics in a research note on Monday, May 1st. Finally, Jefferies Group LLC started coverage on shares of TG Therapeutics in a research note on Tuesday, April 25th. They issued a “buy” rating and a $23.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $23.67.
In other TG Therapeutics news, CFO Sean A. Power sold 59,976 shares of the company’s stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $11.09, for a total value of $665,133.84. Following the transaction, the chief financial officer now owns 477,464 shares in the company, valued at approximately $5,295,075.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 16.70% of the stock is currently owned by corporate insiders.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
